Compare EBON & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBON | AYTU |
|---|---|---|
| Founded | 2010 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 23.4M |
| IPO Year | 2020 | N/A |
| Metric | EBON | AYTU |
|---|---|---|
| Price | $3.35 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 21.8K | ★ 156.8K |
| Earning Date | 08-15-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,337,066.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 104.28 | N/A |
| 52 Week Low | $2.96 | $0.95 |
| 52 Week High | $6.65 | $3.07 |
| Indicator | EBON | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 55.02 |
| Support Level | $3.45 | $2.60 |
| Resistance Level | $3.60 | $2.72 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 56.83 | 33.30 |
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.